Sell AstraZeneca, Says UBS, Which Upgrades European Rivals Including GSK

Dow Jones01-16

UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.

UBS took its ratings on AstraZeneca to sell from buy, while it upgraded GSK to buy from sell. It also upped Novartis and Sanofi to buy from neutral, and Novo Nordisk to neutral from sell.

Analysts led by Matthew Weston say sector valuations are not demanding excluding weight-loss drug maker Novo Nordisk, trading at 13.8 times projected 2024 earnings ex the Danish drugmaker.

On GSK, it forecasts Shingrix sales significantly ahead of consensus, buoyed by a recent China deal. UBS also is more positive on Novartis cancer, chronic spontaneous urticaria and MS drugs than consensus. It is worried about AstraZeneca's exposure to Medicare Part D reform, particularly its oral oncology portfolio.

On Novo Nordisk, "while we can justify current levels based on growth and earnings momentum, we struggle to stretch the valuation further to justify a more positive stance," the analysts said.

AstraZeneca shares slumped 3.7% in premarket trading, while the other pharma stocks saw limited moves.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

4

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2403700856?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-01-16 19:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2403700856","market":"uk","top_or_hot":-1,"title":"Sell AstraZeneca, Says UBS, Which Upgrades European Rivals Including GSK","media":"Dow Jones","content":"<html><head></head><body><p>UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.</p><p>UBS took its ratings on AstraZeneca to sell from buy, while it upgraded GSK to buy from sell. It also upped Novartis and Sanofi to buy from neutral, and Novo Nordisk to neutral from sell.</p><p>Analysts led by Matthew Weston say sector valuations are not demanding excluding weight-loss drug maker Novo Nordisk, trading at 13.8 times projected 2024 earnings ex the Danish drugmaker.</p><p>On GSK, it forecasts Shingrix sales significantly ahead of consensus, buoyed by a recent China deal. UBS also is more positive on Novartis cancer, chronic spontaneous urticaria and MS drugs than consensus. It is worried about AstraZeneca&#39;s exposure to Medicare Part D reform, particularly its oral oncology portfolio.</p><p>On Novo Nordisk, &#34;while we can justify current levels based on growth and earnings momentum, we struggle to stretch the valuation further to justify a more positive stance,&#34; the analysts said.</p><p>AstraZeneca shares slumped 3.7% in premarket trading, while the other pharma stocks saw limited moves.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e6a60bc1b6d5e2e80cc36a43d955eb02\" tg-width=\"841\" tg-height=\"616\"/></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sell AstraZeneca, Says UBS, Which Upgrades European Rivals Including GSK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSell AstraZeneca, Says UBS, Which Upgrades European Rivals Including GSK\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-16 19:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.UBS took its ratings on AstraZeneca to sell from ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVS","symbol_name":"诺华","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2403700856","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2403700856","pubTimestamp":1705404926,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.UBS took its ratings on AstraZeneca to sell from buy, while it upgraded GSK to buy from sell. It also upped Novartis and Sanofi to buy from neutral, and Novo Nordisk to neutral from sell.Analysts led by Matthew Weston say sector valuations are not demanding excluding weight-loss drug maker Novo Nordisk, trading at 13.8 times projected 2024 earnings","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"NVS":"诺华","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4532":"文艺复兴科技持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SNY":"赛诺菲安万特","BK4585":"ETF&股票定投概念","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4007":"制药","AZN":"阿斯利康","BK4578":"CAR-T","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","NVO":"诺和诺德","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4559":"巴菲特持仓","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4568":"美国抗疫概念","BK4588":"碎股","AZN.UK":"阿斯利康制药","BK4207":"综合性银行","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","GSK.UK":"葛兰素史克","0O59.UK":"赛诺菲","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","GSK":"葛兰素史克","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4504":"桥水持仓","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"瑞银称出售阿斯利康，提升包括葛兰素史克在内的欧洲竞争对手的评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"0O59.UK":1.1,"AZN.UK":1.1,"GSK":1,"AZN":0.9,"SNY":0.9,"NVS":0.9,"NVO":0.9,"GSK.UK":0.6},"content_text":"UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.UBS took its ratings on AstraZeneca to sell from buy, while it upgraded GSK to buy from sell. It also upped Novartis and Sanofi to buy from neutral, and Novo Nordisk to neutral from sell.Analysts led by Matthew Weston say sector valuations are not demanding excluding weight-loss drug maker Novo Nordisk, trading at 13.8 times projected 2024 earnings ex the Danish drugmaker.On GSK, it forecasts Shingrix sales significantly ahead of consensus, buoyed by a recent China deal. UBS also is more positive on Novartis cancer, chronic spontaneous urticaria and MS drugs than consensus. It is worried about AstraZeneca's exposure to Medicare Part D reform, particularly its oral oncology portfolio.On Novo Nordisk, \"while we can justify current levels based on growth and earnings momentum, we struggle to stretch the valuation further to justify a more positive stance,\" the analysts said.AstraZeneca shares slumped 3.7% in premarket trading, while the other pharma stocks saw limited moves.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2403700856"}